News | Coronavirus (COVID-19) | February 21, 2023

COVID-19 Vaccination Linked to Fewer Cardiac Events

First U.S. study to show lower risk in patients following SARS-CoV-2 infection

First U.S. study to show lower risk in patients following SARS-CoV-2 infection

Figure A above is a plot of the probability that patients do not develop MACE versus time since their initial SARS-CoV2 infection, stratified by vaccination status. Figure B above is a depiction of hazard ratio associated with MACE according to each examined factor. For example, patients who were fully vaccinated were 59% as likely to achieve MACE compared to patients who were not vaccinated. Lab of Girish N. Nadkarni, MD, MPH, Icahn Mount Sinai


February 21, 2023 — Analyzing the most extensive datasets in the United States, researchers from the Icahn School of Medicine at Mount Sinai have revealed that vaccination against COVID-19 is associated with fewer heart attacks, strokes, and other cardiovascular issues among people who were infected with SARS-CoV-2, the virus that causes COVID-19. 

The research letter, “Impact of Vaccination on Major Adverse Cardiovascular Events in Patients with COVID-19 Infection,” was published in the Journal of the American College of Cardiology on February 20 (DOI: 10.1016/j.jacc.2022.12.006). 

In addition, the research will be presented in a poster session in New Orleans, LA, at the American College of Cardiology’s 72nd Annual Scientific Session Together With World Heart Federation’s World Congress of Cardiology: 

Poster Session 

Title – Prevention and Health Promotion: Population Science
Date/Time – March 5, 2023, 9:30 am to 10:30 am *Central Time*
Location – Poster Hall, Hall F 

It is the first study to examine both full and partial vaccination and the link to major adverse cardiac events (MACE) in the United States, confirming similar analyses performed previously using the Korean COVID-19 registry. Researchers used the National COVID Cohort Collaborative (N3C) database, the largest national comprehensive database on COVID-19. Since its inception in 2020, the N3C has continuously collected and harmonized data from electronic health records of institutions across the country. Included in this study were 1,934,294 patients, 217,843 of whom received mRNA vaccine formulations by Pfizer-BioNTech or Moderna or viral vector technology by Johnson & Johnson. Cox proportional hazards, a statistical technique, was implemented to assess vaccination association with MACE. 

“We sought to clarify the impact of previous vaccination on cardiovascular events among people who develop COVID-19 and found that, particularly among those with comorbidities, such as previous MACE, type 2 diabetes, high cholesterol, liver disease, and obesity, there is an association with a lower risk of complications. While we cannot attribute causality, it is supportive evidence that vaccination may have beneficial effects on a variety of post-COVID-19 complications,” said senior author Girish N. Nadkarni, MD, MPH, Irene and Dr. Arthur M. Fishberg Professor of Medicine at Icahn Mount Sinai, Director of The Charles Bronfman Institute of Personalized Medicine, and System Chief, Division of Data Driven and Digital Medicine (D3M), Department of Medicine. 

“To our surprise, even partial vaccination was associated with lower risk of adverse cardiovascular events,” said first study author Joy Jiang, an MD/PhD candidate in the lab of Dr. Nadkarni. “Given the magnitude of SARS-CoV-2 infection worldwide, we hope our findings could help improve vaccination rates, especially in individuals with coexisting conditions.” 

Further work will be necessary to elucidate the mechanisms involved from an immunological perspective and clarify the role of SARS-CoV-2 subtypes and reinfections in their relationship to the risk of MACE. 

For more information: https://icahn.mssm.edu/ 

RELATED COVID/HEART DAMAGE CONTENT:   

Getting to the Heart of COVID-19 Vaccination and its Cardiovascular Risks   

COVID-19 Surges Linked to Spike in Heart Attacks   

COVID-19 Fallout May Lead to More Cancer Deaths       

Kawasaki-like Inflammatory Disease Affects Children With COVID-19       

FDA Adds Myocarditis Warning to COVID mRNA Vaccine Clinician Fact Sheets       

CMS Now Requires COVID-19 Vaccinations for Healthcare Workers by January 4       

Cardiac MRI of Myocarditis After COVID-19 Vaccination in Adolescents       

Small Number of Patients Have Myocarditis-like Illness After COVID-19 Vaccination       

Overview of Myocarditis Cases Caused by the COVID-19 Vaccine       

Case Study Describes One of the First U.S. Cases of MIS-C       

NIH-funded Project Wants to Identify Children at Risk for MIS-C From COVID-19   


Related Content

News | Cardiovascular Clinical Studies

September 28, 2023 — Merck announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review a ...

Home September 28, 2023
Home
News | Cardiovascular Clinical Studies

September 19, 2023 — A mathematical and computational model of the human heart entirely developed at Politecnico di ...

Home September 19, 2023
Home
News | Cardiovascular Clinical Studies

September 18, 2023 — Pregnant women with a history of substance abuse face a dramatically increased risk of death from ...

Home September 18, 2023
Home
News | Cardiovascular Clinical Studies

September 18, 2023 — Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & ...

Home September 18, 2023
Home
News | Cardiovascular Clinical Studies

September 18, 2023 — Anthos Therapeutics, Inc., a clinical stage company developing innovative therapies for ...

Home September 18, 2023
Home
News | Cardiovascular Clinical Studies

September 14, 2023 — Myocardial infarction, the number one cause of sudden death in adults and the number two cause of ...

Home September 14, 2023
Home
News | Cardiovascular Clinical Studies

September 12, 2023 — Mineralys Therapeutics, Inc. has presented final results from the Target-HTN Phase 2 trial of ...

Home September 12, 2023
Home
News | Cardiovascular Clinical Studies

September 12, 2023 — Merck announced new analyses from studies of sotatercept, Merck’s novel investigational activin ...

Home September 12, 2023
Home
News | Cardiovascular Clinical Studies

September 8, 2023 — Imbria Pharmaceuticals, Inc., a clinical stage, cardiometabolic company dedicated to developing ...

Home September 08, 2023
Home
Subscribe Now